<p>The most common adverse reactions observed in single agent Ramucirumab-treated gastric cancer patients at a rate of &ge;10% and &ge;2% higher than placebo were hypertension and diarrhea.<br />
<br />
The most common adverse reactions observed in patients treated with Ramucirumab with paclitaxel at a rate of &ge;30% and &ge;2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.<br />
<br />
The most common adverse reactions observed in patients treated with Ramucirumab with erlotinib at a rate of &ge;30% and &ge;2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. The most common laboratory abnormalities at a rate of &ge;30% and &ge;2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.<br />
<br />
The most common adverse reactions observed in patients treated with Ramucirumab with docetaxel at a rate of &ge;30% and &ge;2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.<br />
<br />
The most common adverse reactions observed in patients treated with Ramucirumab with FOLFIRI at a rate of &ge;30% and &ge;2% higher than placebo with FOLFIRI were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.<br />
<br />
The most common adverse reactions observed in single agent Ramucirumab-treated HCC patients at a rate of &ge;15% and &ge;2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. The most common laboratory abnormalities at a rate of &ge;30% and a &ge;2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia.</p>